Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies
Articles
THERAPEUTIC FOCUS - Targeted Payload Therapies Radiate Potential to Attack Various Cancers
Kaushik J. Dave, PhD, MBA, and Dragan Cicic, MD, MBA, indicate that alpha-particle emitters, such as bismuth-213 or actinium-225, may be more effective and efficient at killing cancerous cells not currently treated with radiation while simultaneously decreasing nonspecific cytotoxic effects.
iDEL Therapeutics Partners with Daiichi Sankyo to Evaluate Novel Cancer Drug Delivery Platform
iDEL Therapeutics has entered a multi-year research collaboration with Daiichi Sankyo to evaluate a multi-drug conjugate delivered using its synthetic shuttle technology. The preclinical work will compare the candidate against an antibody-drug conjugate and explore ways to overcome cellular uptake and endosomal entrapment.
Emvena Therapeutics Launches With Funding to Develop Placenta-Targeted Preeclampsia Treatment
Emvena Therapeutics has emerged from stealth to advance a placenta-targeted mRNA approach to treating preeclampsia, a serious pregnancy complication.
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
Basel, Switzerland, and London, UK – Lonza, a contract development and manufacturing organization (CDMO), and Engitix, a global leader in...Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
FREDERICK, MD, – Cartesian Therapeutics, Inc., a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced a...CONTROLLED RELEASE - Precision in Every Dose: Advancing Controlled Release for Small Molecule Therapeutics
Controlled release technologies are helping small molecule therapeutics deliver more consistent drug exposure, improve patient adherence, reduce dosing frequency, and support more precise treatment through advanced formulation and delivery strategies.
EXECUTIVE INTERVIEW - Intensity Therapeutics: Providing Cancer Patients With Treatments That Work
Lew Bender, Founder and CEO of Intensity Therapeutics, discusses the company’s science, clinical program, the drug development process, and more.
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
Martinsried, Germany, and Marseille, France - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of...OBI Pharma Enters ADC Collaboration With TegMine Therapeutics Utilizing GlycOBI & TegMiner Enabling Technologies
OBI Pharma, Inc. and TegMine Therapeutics, Inc. have entered into an ADC-related Master Services Agreement (MSA). Under the terms of...PROTEIN BARCODING - Streamlining mRNA Therapeutic & Vaccine Development
Meredith Carpenter, PhD, reviews how lipid nanoparticles have emerged as a powerful tool for delivery due to their low immunogenicity compared to viral vectors, along with their ability to encapsulate and protect nucleic acids and facilitate their entry into cells.
















